Private equity firms are interested in acquiring Bausch + Lomb (BLCO.US), which has surged over 5%.

According to foreign media reports, private equity firms are interested in acquiring American Bausch Lomb (BLCO.US), which has risen by 8.51% as of the time of publication. Foreign media cited sources familiar with the matter on Wednesday, reporting that private equity firms including Blackstone Inc., Advent International, TPG Capital, CVC Capital, and Hellman & Friedman are evaluating potential acquisition offers for Bausch Lomb. Bidders can reveal their acquisition intentions before the deadline on Friday. It is currently not guaranteed that the sale process will result in a final deal, and the company is exploring other options, including refinancing some of its debt. The potential sale price of Bausch Lomb is not clear yet, but it may be higher than the current enterprise value of $11.5 billion including debt. Previously, foreign media reported last Saturday that Bausch Lomb is considering a sale to address concerns raised by Apollo Global Management Inc., among other financial institutions, about its separation from its parent company Bausch Health (BHC.US). The Canadian eye care company is working with advisors from Goldman Sachs Group, Inc. to evaluate buyer interest. The company split from Bausch Health in 2022.